Hardy J R, Maclean G D, Foote G A, Harvey V J
Department of Clinical Oncology, Auckland Hospital, New Zealand.
Aust N Z J Obstet Gynaecol. 1987 May;27(2):146-9. doi: 10.1111/j.1479-828x.1987.tb00967.x.
Nineteen patients with advanced recurrent carcinoma of the uterine cervix received platinum based chemotherapy between February 1982 and April 1984. All patients had received prior pelvic irradiation. Eleven patients received combination chemotherapy with platinum, vinblastine and bleomycin (PVB), and 8 patients received a regimen of platinum and 5-fluorouracil (PF). Two patients achieved a complete response and 4 patients achieved a partial response, a total response rate of 33%. Five out of 6 responders received PVB. The median survival (MS) was 8 months (1-38) months from the first treatment with cytotoxic chemotherapy. In those patients achieving a response, MS was 13.5 months (6-38+ months) with 1 patient alive at 38 months, compared to an MS of 5 months (1-15 months) in those patients without response. Toxicity was significant with nausea and vomiting in the majority of patients. Two patients refused treatment after the first course because of toxicity. The morbidity of treatment was such that despite an encouraging response rate, particularly to PVB (45%), the routine use of such treatment must be questioned.
1982年2月至1984年4月期间，19例晚期复发性宫颈癌患者接受了铂类化疗。所有患者此前均接受过盆腔放疗。11例患者接受了铂、长春碱和博来霉素联合化疗（PVB），8例患者接受了铂和5-氟尿嘧啶方案（PF）。2例患者达到完全缓解，4例患者达到部分缓解，总缓解率为33%。6例缓解者中有5例接受了PVB治疗。自首次接受细胞毒性化疗起，中位生存期（MS）为8个月（1 - 38个月）。在缓解的患者中，MS为13.5个月（6 - 38 +个月），有1例患者在38个月时仍存活，而未缓解患者的MS为5个月（1 - 15个月）。大多数患者出现了严重的恶心和呕吐毒性反应。2例患者在第一个疗程后因毒性反应拒绝治疗。尽管缓解率令人鼓舞，尤其是对PVB的缓解率（45%），但这种治疗的发病率使得其常规使用必须受到质疑。
